← Browse by Condition
Medical Condition

potentially resectable

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT07323056 Phase 2
Recruiting

Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

Enrollment
36 pts
Location
China
Sponsor
Shanghai Pulmonary Hospital, S...
View Trial →